Anti-abortion plaintiffs argued against the FDA’s expanded access to the abortion pill in a case that could have significant implications for the pharma industry.
5 healthcare takeaways from President Biden’s 2024 State of the Union address
President Biden emphasized more drug pricing reform and highlighted his administration’s commitment to reproductive rights in the State of the Union address.
How the CDC plans to improve public health messaging in a post-COVID world
Even as the COVID-19 pandemic recedes from memory, the CDC is still grappling with public distrust in the wake of its communications blunders. Here’s how the agency plans to rebuild trust.
PBM trade group pushes back on House bill targeting spread pricing
The House Committee on Oversight and Accountability recently voted to advance another PBM reform bill in Congress. Here’s how the PBM industry responded.
Bernie vs. Big Pharma: Senate hearing exposes rift over high drug prices
CEOs from Johnson & Johnson, Merck and Bristol Myers Squibb all testified at a Senate HELP committee hearing that questioned them about high drug prices. But many of the same arguments ensued with the chair Sen. Bernie Sanders, (I-VT).
The Inflation Reduction Act’s Medicare negotiation process kicks off
Sanders has threatened to subpoena J&J CEO Joaquin Duato and Merck CEO Robert Davis if they don’t agree to appear in a Senate HELP hearing over high drug costs later this month.
HHS may blaze a new trail by recommending loosened marijuana restrictions
The FDA’s approval of Florida’s plan to import drugs is official. Healthcare marketers will have to develop communication around the law’s process and impact to patients and stakeholders.
FDA OKs Florida’s plan to import drugs from Canada